Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ eBay Non-GAAP EPS of $1.60 beats by $0.09, revenue of $3.1B beats by $80M (SeekingAlpha) +++ EBAY Aktie +3,07%

IPSEN Aktie

 >IPSEN Aktienkurs 
158.4 EUR    +0.6%    (TradegateBSX)
Ask: 160.3 EUR / 7 Stück
Bid: 159.4 EUR / 7 Stück
Tagesumsatz: 6 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IPSEN Aktie über LYNX handeln
>IPSEN Performance
1 Woche: -1,6%
1 Monat: -6,8%
3 Monate: -5,9%
6 Monate: +16,5%
1 Jahr: +47,3%
laufendes Jahr: +32,1%
>IPSEN Aktie
Name:  IPSEN S.A. PORT. EO 1
Land:  Frankreich
Sektor:  Gesundheit
ISIN/ Wkn:  FR0010259150 / A0ESMG
Symbol/ Ticker:  I7G (Frankfurt)
Kürzel:  FRA:I7G, ETR:I7G, I7G:GR
Index:  -
Webseite:  https://www.ipsen.com/
Profil:  Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology, rare diseases, and neuroscience. Founded in 1929..
>Volltext..
Marktkapitalisierung:  12638.16 Mio. EUR
Unternehmenswert:  11633.42 Mio. EUR
Umsatz:  4007.51 Mio. EUR
EBITDA:  1920.71 Mio. EUR
Nettogewinn:  507.69 Mio. EUR
Gewinn je Aktie:  6.14 EUR
Schulden:  953.97 Mio. EUR
Liquide Mittel:  1951.41 Mio. EUR
Operativer Cashflow:  1292.29 Mio. EUR
Bargeldquote:  1.14
Umsatzwachstum:  13.63%
Gewinnwachstum:  14.45%
Dividende je Aktie:  1.6 EUR
Dividendenrendite:  1.05%
Dividendenschätzung:  0.98%
Div. Historie:  03.06.26 - 1.6€
04.06.25 - 1.4€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  IPSEN
Letzte Datenerhebung:  05.08.26
>IPSEN Kennzahlen
Aktien/ Unternehmen:
Aktien: 82.71 Mio. St.
Frei handelbar: 40.96%
Leerverk. Aktien: -
Rückkaufquote: 0.58%
Mitarbeiter: 5535
Umsatz/Mitarb.: 0.68 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 5.71%
Bewertung:
KGV: 25.34
KGV lG: 11.31
KUV: 3.16
KBV: 2.75
PEG-Ratio: 1.65
EV/EBITDA: 6.06
Rentabilität:
Bruttomarge: 72.42%
Gewinnmarge: 12.67%
Operative Marge: 30.13%
Managementeffizenz:
Gesamtkaprendite: 7.17%
Eigenkaprendite: 11.47%
>IPSEN Peer Group
 
04.08.26 - 13:01
 Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion (PR Newswire)
 
First partnered TriSTAR program advances into IND-enabling development Industry-leading expert in T-cell engager discovery and immune-cell activation, Saso Cemerski, joins as Senior Vice President, Head of Immunology, to accelerate expansion of Marengo's precision Vβ-directed T-cell......
03.08.26 - 18:03
 IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026 (GlobeNewswire EN)
 
Aggregated presentation by day and by market...
03.08.26 - 14:31
 Jefferies cuts Ipsen on Camurus competition risk (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 18:06
 Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026) (GlobeNewswire EN)
 
Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)...
30.07.26 - 12:45
 Ipsen slips despite raising outlook on broad-based drug sales growth (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 07:48
 Ipsen S.A. Non-GAAP EPS of €7.33, revenue of €2.19B; upgrades FY 2026 financial guidance (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 07:30
 Ipsen hebt Prognose für 2026 nach Umsatzsprung im ersten Halbjahr an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 07:03
 Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance (GlobeNewswire EN)
 
PARIS, FRANCE, 30 July 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2026....
29.07.26 - 19:03
 Ipsen nominates Catherine Bradley to its Board of Directors as independent Director (GlobeNewswire EN)
 
Ipsen appoints Catherine Bradley as independent Director to its Board of Directors...
27.07.26 - 18:03
 IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026 (GlobeNewswire EN)
 
Aggregated presentation by day and by market...
24.07.26 - 16:06
 Ipsen phase 3 Bylvay trial in biliary atresia misses primary goal (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.07.26 - 13:54
 Health Care Roundup: Market Talk (WSJ EN)
 
Find insight on Roche Holding, CSL, and Ipsen in the latest Market Talks covering Health Care....
24.07.26 - 09:30
 Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease (WSJ EN)
 
Bylvay missed the study's primary objective of showing an improvement in native liver survival rates compared to placebo....
24.07.26 - 07:03
 Ipsen provides update on Phase III BOLD trial in biliary atresia (GlobeNewswire EN)
 
PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a Kasai hepatoportoenterostomy (HPE) did not meet the primary endpoint of improvement in native liver survival vs placebo. Current topline data is in line with the well-established safety profile of odevixibat in approved indications. Characterized as a rapidly progressive and complex condition, BA is the leading cause of paediatric liver transplant, with no approved therapeutic options beyond Kasai HPE or liver transplant surgery....
22.07.26 - 07:03
 Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen′s Rare Disease pipeline (GlobeNewswire EN)
 
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody....
21.07.26 - 18:03
 IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2026 (GlobeNewswire EN)
 
Aggregated presentation by day and by market...
15.07.26 - 18:03
 IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026 (GlobeNewswire EN)
 
Aggregated presentation by day and by market...
09.07.26 - 18:03
 Ipsen - June 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
 
Monthly information relative to the total number of voting rights and shares composing the share capital...
09.07.26 - 07:03
 Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. (GlobeNewswire EN)
 
PARIS, FRANCE – 9 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive topline results from its Phase III BEOND migraine program evaluating Dysport® (abobotulinumtoxinA) for the prevention of episodic (E-BEOND) and chronic migraine (C-BEOND) in adults. Both the E-BEOND and C-BEOND trials met their primary endpoints, a reduction in monthly migraine days versus placebo....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Philosophen verderben die Sprache, Poeten die Logik, und mit dem Menschenverstand kommt man durchs Leben nicht mehr. - Friedrich Johann Christoph Schiller
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!